* Horizon Pharma PLC submits supplemental NDA for RAVICTI
oral liquid to expand age range for management of urea cycle
disorders
Source text for Eikon:
Further company coverage:
(Bengaluru…
The post BRIEF-Horizon Pharma submits supplemental NDA for RAVICTI oral liquid appeared first on NASDAQ.